Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C
← catalyst calendarNCT05905926 · readout ≤ 1,806 d
Sponsored by Ardelyx (industry) · ARDX — their whole pipeline →.
Phase
Phase 3
Status
Enrolling by invitation
Study type
Interventional
Design
Na · None · Health services research
Enrollment
150estimated
Sites
27
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-02-17 | actual | When the study began enrolling |
| Primary completion | Jul 2031 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2031 | estimated | The whole study's end, after follow-up |
| First posted | 2023-06-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Irritable Bowel Syndrome With Constipation (IBS-C)
Intervention
- Drug: Tenapanor — also filed as Ibsrela
Primary outcomes
what the primary-completion date above is the date OFSafety Measure Assessment (Adverse Event)
measured 40 weeks
Safety Measure Assessment (ECG)
measured 40 weeks
Permalink · ARDX's whole pipeline · Catalyst calendar · Every registered study · What changed